(Q82740818)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

17 January 2020

main subject

1 reference

inferred from title

hepatocellular carcinoma

1 reference

Sophy Ting-Fang Shih

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Steve Crowley

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jin-Chuan Sheu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

Journal of the Formosan Medical Association

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

39-55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Primary hepatocellular carcinoma in alaskan natives, 1969–1979

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Secondary prevention of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Efficacy of a surveillance program for early detection of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Serum alphafetoprotein in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Hepatocellular carcinoma: US evolution in the early stage

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Mass screening for hepatocellular carcinoma: Experience in Hokkaido, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Clinical impact of screening first-degree relatives of patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Health-State Utilities and Quality of Life in Hepatitis C Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Quality of life and cognitive function in hepatitis C at different stages of liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Estimation of utilities for chronic hepatitis C from SF-36 scores

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Subclinical hepatocellular carcinoma in Hong Kong Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960020-4

7 January 2021

10.1016/S0929-6646(10)60020-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20123585%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference